Development Terminated
|
| GW420867X/HBY1293 |
GlaxoSmithKline |
JAIDS 2000; also summer IAS meeting |
| ALX40-4C |
Allelix Pharmaceuticals |
Formulation difficulties, lack of efficacy |
| AMD3100 |
AnorMed Inc. |
Cardiac arrhythmias at high doses, lack of efficacy at low |
| PD-178390 |
Parke-Davis |
Casualty of Pfizer merger |
| CI-1012 |
Parke-Davis |
Casualty of Pfizer merger |
| PNU-142721 |
Pharmacia & Upjohn |
Casualty of P&U’s decision to leave HIV field |
| NSC 651016 |
Pharmacia & Upjohn |
Casualty of P&U’s decision to leave HIV field |
| UC781 |
Biosyn Inc. |
Being developed as topical microbicide |
| zintevir/AR-177 |
Antigenics (formerly Aronex) |
Terminated subsequent to takeover and poor results |
Clinical Hold
|
| emtricitabine/FTC/Coviracil |
Triangle/Abbott |
Submission of NDA to be “significantly delayed“ |
| (-)dOTC/BCH-10618/SPD754 |
Shire Pharmaceuticals PLC |
Deaths in monkeys |
| capravirine/S-1153/AG-1549 |
Agouron (Pfizer) |
Vasculitis in dogs may mean curtains for capravirine |
| mozenavir/DMP-450 |
DuPont (now BMS) |
Electro-cardiographic abnormalities in animals |
Glacial Development
|
| Pentafuside/T-20 |
Trimeris/Roche |
Phase III; awaiting construction of peptide plant |
| T-1249 |
Trimeris/Roche |
Phase I; longer half-life may allow QD dosing |
Late Pipeline
|
| tenofovir/Viread |
Gilead |
FDA hearing set for October 3; Expanded Access info |
| emivirine/MKC-442/Coactinon |
Triangle/Abbott |
Triangle hopes to file NDA by year end; ICAAC |
Middle Pipeline
|
| atazanavir/BMS-232632 |
Bristol-Myers Squibb |
Moving slowly but deliberately through phase II |
| tipranavir |
Boehringer-Ingelheim |
“Trinity of major obstacles,” paper at summer IAS |
| VX-175/GW433908 |
Vertex/GlaxoSmithKline |
Amprenavir prodrug, PK dose-ranging at 8th CROI |
| SCH-C |
Schering/Praecis |
Recently released from clinical hold, but future dim; IAS paper |
| PRO 542 |
Progenics Pharmaceuticals |
Phase II; being studied in combination with T-20 |
| DPC-083 |
DuPont (now BMS) |
Eyed to hit market in 2003; paper at 7th CROI |
Deep Pipeline
|
| DADP/amdoxovir |
Triangle Pharmaceuticals |
Phase I/II dose ranging study presented at 8th CROI |
| TMC-120, 125 |
Tibotec/Virco |
“Resistant repellent”; Russian-Polish study at 8th CROI |
| TMC-126 |
Tibotec/Virco |
Paper at 8th CROI |
| DPC-961, DPC-963 |
DuPont (now BMS) |
Atazanavir may take priority over these |
| Calanolide-A |
SarawakMed |
Paper on this at 7th CROI |
| GPG-NH2 |
Tripep AB/Karolinska Institute |
Early activity in humans not too impressive |
| SCH-D |
Schering/Praecis |
Follow-up compound to SCH-C |
| UK-427,857 |
Pfizer |
Said to be moving into Phase I “soon” |
| DPC-681, DPC-684 |
DuPont (now BMS) |
Phase I studies on-going; paper at 8th CROI |
| AMD-3465, 8445, 8664 |
AnorMed |
AMD8664 is orally available analogue of AMD3100 |
| TAK-779 |
Takeda Pharmaceuticals |
Being studied in combination with T-20 |
| HE2000 |
Hollis-Eden Pharmaceuticals |
Phase I/II enrolling in U.S.; info from company; other |
| PRO 140 |
Progenics Pharmaceuticals |
Moving into Phase I/II; press release |
| PRO 367 |
Progenics Pharmaceuticals |
Phase I recently completed |
| TNX-355/Hu5A8 |
Tanox Biosystems, Inc. |
Phase I clinical study began 8/1/01 |
| PEHRG214 |
Virionyx |
Phase I at Boston Deaconess Hospital, 3/01 |
| HIV NCp7 |
Achillion Pharmaceuticals |
Pre-clinical; also in Phase I for HBV; see CRADA announcement |
| SPD-756 |
Shire Pharmaceuticals PLC |
Formerly BCH-13520; company press release |
| Fd4C/ACH-126,443 |
Achillion Pharmaceuticals |
L. Dunkle on this, but will it go the way of other “F” drugs? |
| 5-helix |
Howard Hughes Medical Inst. |
Science 2001, 291:884-888 |
| ADA (azidocarbonamide) |
Hubriphar |
Phase I/II: AIDS 2001, 15:33-45 |
| S1360 |
Shionogi Pharmaceuticals |
Phase I/II PK currently enrolling Cornell, Columbia, UAB |
| TAK-449 |
Takeda Pharmaceuticals |
Company officials refused request for information |
| T-649 |
Trimeris/Roche |
Similar to T-1249; paper at 7/01 IAS meeting |
Missing in Action
|
| L-756,423/MK-944A |
Merck |
Reportedly moving into Phase II/III; paper at 7th CROI |
| AG-1776/JE-2147 |
Agouron (Pfizer) |
All appearances suggest this drug is history |
| L-708,906, L-731,988 |
Merck |
Hazuda, D.J., et al., Science 287 (Jan. 28):646 (also, Science News) |
| Didox, Trimodox |
Molecules for Health |
Ribonucleotide reductase inhibitors — circa 1995 |
| AOP-RANTES |
Gryphon Sciences |
Animal (mouse) data only, J Virol 5/99; paper at summer IAS |
| FP-21399 |
Lexigen Pharmaceuticals |
Bruce Dezube again: J Infect Dis 2000 182:607-10 |
| PRO2000 |
Genetics (formerly Procept) |
Being tested as topical microbicide at Fenway Center |
| HGTV43 |
Enzo Biochem, Inc. |
Paper at summer IAS meeting |
| SJ-3366 |
Samjin Pharmaceuticals Ltd. |
Paper at 14th Intl. Conf. on Antiviral Research, 4/01 |
